Last reviewed
7/8/26 → 7/10/26
Conviction●●●●○4 of 5
Research target$124.02Snapshot target
Thesis statusSTRENGTHENEDLast reviewed 7/10/26
Market cap$163.61BSnapshot value
Research history
See all ABT changes ↗What changed
Conviction
1 → 4
Target
— → $124.02
Thesis status
NEEDS_MORE_DATA → STRENGTHENED
Last reviewed
Not reviewed → 7/8/26
Target
— → $124.02
CGM leader plus diagnostics/cancer-screening expansion; diversified med-tech and nutrition platform; Libre remains the core healthspan engine.
FreeStyle Libre/Lingo CGM expansion; Exact Sciences acquisition closed 2026-03-23; diagnostics/cancer-screening growth vector; upcoming Q2 earnings watch.
Diversification reduces CGM purity; 5-year underperformance vs broad equities; med-tech segment cyclicality; GLP-1 long-term diabetes disruption.
Constructive: X chatter centers on FreeStyle Libre, Exact Sciences integration, and the upcoming Q2 print; bullish on metabolic-health/diagnostics exposure but watching margins.
Snapshot · 7/10/26🟢 Confirmed · ins+$1.3M(3buy👥) · 13F 14+/10- · short↑0.21
Snapshot · 7/10/26